Concepedia

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

Justin M. Watts, Maria R. Baer, Jay Yang, Thomas Prébet, Sang‐Min Lee, Gary J. Schiller, Shira Dinner, Arnaud Pigneux, Pau Montesinos, Eunice S. Wang,

The Lancet Haematology · 2022 · 117 citations · 20 references

DOIFull text

Open access

Concepts

References

20

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat et al. · New England Journal of Medicine · 2020 · 2.8K citations · Full text

, , +3

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.7K citations

, , +17

IDH mutation impairs histone demethylation and results in a block to cell differentiation

Chao Lü, Patrick S. Ward, Gurpreet S. Kapoor et al. · Nature · 2012 · 2K citations

, , +14

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Bruce D. Cheson · Blood · 2006 · 1.6K citations

, , +9

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea et al. · Blood · 2017 · 1.5K citations · Full text

, , +13